Thalidomide in mycosis fungoides

Brightman, Lori; Demierre, Marie‐France

doi:10.1016/j.jaad.2005.01.104

Cited by 8 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(75) While improving the patient’s disease, thalidomide also reduced the pruritus experienced by this patient from a 6/10 down to a 2/10. (76) Thalidomide has been shown to reduce the itch associated with uremic pruritus and Hodgkin’s disease in the past, however the exact mechanism by which thalidomide accomplishes this is unknown.…”

Section: Mechanism Of Pruritus In Ctcl: Potential Mediators Involvedmentioning

confidence: 94%

Pruritus in cutaneous T-cell lymphoma: A review

Ahern

Gilmore

Poligone

2012

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Background Pruritus can be a distressing and even debilitating symptom for patients with cutaneous T-cell lymphoma (CTCL). To date, few studies have evaluated the pathophysiology of this symptom. Due to this, therapy for pruritus in CTCL has mainly relied on those therapies that target and treat the lymphoma. For patients living with CTCL that relapses or becomes refractory to treatment, and who continue to experience severe itch, this lymphoma-targeted treatment may not be enough to combat their pruritus. Therefore, other itch-targeted therapies are needed for use in this disease Objective Evaluate the current evidence regarding the mechanism of action and treatments for pruritus associated with cutaneous T-cell lymphoma. Methods An explicit and thorough search was restricted to all peer-reviewed literature available through MEDLINE (1950 to September 2011) and pubmed.org. Search terms used were pruritus, cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), and Sézary Syndrome (SS). All studies that involved pruritus in either CTCL, MF, or SS were evaluated by all three authors. Results The current literature helps to identify therapies and possible mechanisms for treating patients with CTCL associated pruritus. . Limitation Most studies were pre-clinical. Only studies involving mechanisms of action or treatment were included Conclusion A guideline is necessary to assist in the treatment of pruritus in CTCL and additional studies are necessary to uncover the exact mechanism(s) of action.

show abstract